These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 8683700)

  • 1. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
    Lee WR; Hanlon AL; Hanks GE
    J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
    Aref I; Eapen L; Agboola O; Cross P
    Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.
    Kestin LL; Vicini FA; Ziaja EL; Stromberg JS; Frazier RC; Martinez AA
    Cancer; 1999 Oct; 86(8):1557-66. PubMed ID: 10526285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
    Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
    J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate.
    Zietman AL; Tibbs MK; Dallow KC; Smith CT; Althausen AF; Zlotecki RA; Shipley WU
    Radiother Oncol; 1996 Aug; 40(2):159-62. PubMed ID: 8884970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
    Zagars GK
    J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postneoadjuvant hormone PSA levels and prognosis in locally advanced prostate cancer.
    Velasco J; Tekyi-Mensah S; Bolton S; Forman JD
    Urology; 1999 Aug; 54(2):325-8. PubMed ID: 10443733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
    Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen spikes after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
    Kavadi VS; Zagars GK; Pollack A
    Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.
    Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
    J Urol; 1999 Apr; 161(4):1199-203; discussion 1203-5. PubMed ID: 10081869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
    Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biochemical control after external radiotherapy in localized prostatic cancer: results of a modern cohort].
    Zapatero Laborda A; López Rodríguez M; Mínguez Martínez R; Rodríguez F; Pérez-Torrubia A
    Actas Urol Esp; 2000 Jan; 24(1):10-8. PubMed ID: 10746369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.